Jason Warnock, Chief Revenue Officer of Flora Growth and Robert Galarza, CEO of TruTrace on why they are leading the way in adopting, and developing, best-in-class technologies

OVER the last few years, we have seen a proliferation of jurisdictions around the world beginning to legalize and adopt cannabis as a medical treatment.

This growth has led to an influx of new breeders and growers and a profusion of new cannabis strains.

Unfortunately, this rapid growth fails to recognize the fact that cannabis is highly variable with potentially significant chemical changes between batches and lots.

These subtle changes in the chemical expression of various strains, whether by genetic structure or environmental conditions, may have significant clinical effects on the patients using this treatment option.